Attached files

file filename
10-K - FORM 10-K - GALECTIN THERAPEUTICS INCd10k.htm
EX-23.1 - CONSENT OF MCGLADREY & PULLEN, LLP - GALECTIN THERAPEUTICS INCdex231.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - GALECTIN THERAPEUTICS INCdex312.htm
EX-21.1 - SUBSIDIARIES OF PRO PHARMACEUTICALS, INC. - GALECTIN THERAPEUTICS INCdex211.htm
EX-32.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 906 - GALECTIN THERAPEUTICS INCdex322.htm
EX-23.2 - CONSENT OF CATURANO AND COMPANY, INC. - GALECTIN THERAPEUTICS INCdex232.htm
EX-31.1 - CERTIFICATION OF CEO AND PRESIDENT PURSUANT TO SECTION 302 - GALECTIN THERAPEUTICS INCdex311.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Pro-Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Theodore Zucconi, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

March 15, 2011    

/s/    Theodore D. Zucconi

    Name:   Theodore D. Zucconi, Ph.D.
    Title:  

Chief Executive Officer and President

(principal executive officer)